Article and Video CATEGORIES

Cancer Journey

Search By

Blood Cancer Video Library - What Is The Significance Of IGHV Mutations And How Are They Assessed?
Tue, 06/21/2016 - 00:00
Author
GRACE Videos and Articles
Image

We recently joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies.

Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided provoking and educational discussions on the significance of IGHV mutations and how they are assessed. We invite you to watch this first video from our Blood Cancers Library Video collection.

Stay tuned for more educational videos soon to come!


TRANSCRIPT

What is the significance of IGHV mutations and how are they assessed?

Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute

 

Now we are going to talk about whether there’s still a role for chemotherapy or chemoimmunotherapy in the treatment of CLL, now in the era of novel kinase inhibitors. This is a very important topic because we have some new recent exciting data on the potential benefits of chemotherapy. As you know, the standard chemoimmunotherapy treatment now for fit younger CLL patients is something called FCR (fludarabine, cyclophosphamide and rituximab) and this is a treatment given infusionally by vein for three days, every four weeks, for about six months. This treatment has been studied in multiple large trials and we now have long follow up from three of them that report specifically on a genetic subgroup of CLL, a subgroup of something called mutated IGHV, which I’ll explain more in a minute. These three trials all report that people with mutated IGHV CLL can have extremely long duration of remission after FCR treatment. In fact, at twelve years, about 60% of such people are still in remission and likely many of them are cured, many of them have no evidence of disease by the most sensitive tests. So, what does it mean to have mutated IGHV? The IGHV test is something that we do on the CLL cells. CLL cells come from a normal cell called a B-lymphocyte, and B-lymphocytes have an antibody gene in them. The antibody gene can get changed over the course of the life cycle of the B-lymphocyte. All CLL cells have the same one and it turns out that how much the antibody gene has changed from the day you were born has a very strong impact on the way CLL behaves. So, a so-called mutated IGHV shows much greater change from the way it was when you were born in the antibody gene. This has been found empirically to associate with better behaving CLL, longer time to treatment and better response to treatment, and now with these FCR studies, perhaps even cure with FCR. The other subgroup of CLL, the unmutated group, has an antibody gene in their CLL cells that looks much more similar to how the gene was when you were born which is why it’s called unmutated. It is associated with more steadily progressive disease and after FCR; we see more steady relapse although the median duration remission is still on the order of about four to five years.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Terapias Dirigidas de Cáncer de Pulmón 2023
Video
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras. En esta serie de videos los Doctores Fernando Diaz, Luis Raez, Luis Corrales, Estelamari Rodriguez y Alberto Chiappori presentan el Panel de Discusión donde hablan sobre temas relevantes del cáncer de pulmón. 
Image
Terapias Dirigidas de Cáncer de Pulmón 2023
Video
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras. En esta serie de videos los Doctores Fernando Diaz, Luis Raez, Luis Corrales, Estelamari Rodriguez y Alberto Chiappori presentan el Panel de Discusión donde hablan sobre temas relevantes del cáncer de pulmón. 
Image
September 2023 Blood Cancer OncTalk
Article
The September 2023 Blood Cancer OncTalk has now ended.  Videos are available OnDemand! The full unedited versions of the September 2023 Blood Cancer OncTalk, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.   The full videos are available on our YouTube channel via this link:  https://youtube.com/playlist?list=PLWsyUmdjLXhG4km7yALHmLjQSeUQg-36x

Forum Discussions

Stan - Thank you once again for your kind words.  Thank you as well for your donation.  As you know, your donation helps us to exist and continue to fulfill our...

Hi Stan, It's good to hear your voice and know your cheesecakes are still making the rounds.  Though I'm sure startling, I imagine some of those little pockets of the house...

Hi Rutbats,  Welcome to GRACE and thanks for the kind words. 

 

We can't say what you should or shouldn't do and I can't say why your RA doc made their...

Thank you very much for your quick answer, Janine.

I have an appointment with a pulmonologist in 10 days. I will summarize the conversation with him here, so that other people...

Glad to know you're moving forward with a pulmonologist.  The more you know the better the conversation with your pulmonologist.  Remember you can help your docs know what level their conversation...

Hi Terry, Welcome to Grace. 

I saw this exact post somewhere else months back and the only response was to a lab.  I hope that doesn't happen here, we don't allow...

Recent Comments

JOIN THE CONVERSATION
Hi Stan, It's good to hear…
By JanineT GRACE … on Fri, 12/01/2023 - 07:14
Thank you Stan, for your kind words.
By dbrock on Thu, 11/30/2023 - 11:55
Glad to know you're moving…
By JanineT GRACE … on Mon, 11/27/2023 - 11:27
Thank you very much for your…
By rutbats on Mon, 11/27/2023 - 08:07